WuXi AppTec wages buyback campaign as U.S. pressure mounts
The drug services provider has been battling to shore up its share price and suffered a sharp sell-off after being added to a U.S. list of firms with suspected military…
BRIEF: Shimai Pharma gets CSRC nod for Hong Kong IPO
Zhejiang Shimai Pharmaceutical Co. Ltd., a developer of T-cell engager (TCE) therapies, has been cleared by the China Securities Regulatory Commission (CSRC) for its overseas listing, marking an important step…
Innovent’s $10.5 billion deal marks new model for China drugmakers
The Chinese biotech has added a major Pfizer collaboration to its growing roster of global deals, this time with a tighter commercial and profit-sharing partnership Key Takeaways: Co-commercialization deals…
BRIEF: WuXi Biologics maintains full-year revenue guidance for up to 17% growth
Drug development services company WuXi Biologics (Cayman) Inc. (2269.HK) announced on Sunday that it had secured 69 new integrated projects as of April 30, with approximately two-thirds originating from clients…
Investors pile onto TenNor IPO with hopes for new type of gastric drug
The biotech enjoyed a standout Hong Kong share debut after hailing its novel anti-bacterial drug, now undergoing late-stage clinical tests, as a potential gamechanger Key Takeaways: The TenNor Therapeutics IPO…
Then there were two: BeOne moves beyond single-blockbuster dependence
The company’s Sonrotoclax is the first newly approved BCL-2 inhibitor in the U.S. in nearly a decade, giving BeOne a potential new hit beyond its Zanubrutinib blood cancer therapy Key…
Precision-drug maker Impact Therapeutics ignites IPO frenzy
The biotech scored a strong debut on the Hong Kong stock market after launching a targeted “synthetic lethality” drug that can kill off mutated cancer cells Key Takeaways: The company’s…
Recent Articles
WuXi AppTec wages buyback campaign as U.S. pressure mounts
2359.HK
603259.SHG
Then there were two: BeOne moves beyond single-blockbuster dependence
6160.HK
688235.SHG
ONC.US
RELATED ARTICLES
-
Top battery equipment supplier gets regulatory nod, hoping to follow CATL’s success
300450.SHE - Jacobio Pharma poised to turn a profit from precision cancer drugs
-
InSilico lands drug discovery deal after Hong Kong IPO
3696.HK
- Hong Kong to welcome world-leading siRNA company as Ribo launches its IPO
- China’s biopharma sector enters the New Year on a high
- Mega licensing deal lifts 3SBio profits but core sales slip
